CDH11 inhibits proliferation and invasion in head and neck cancer

Songlin Piao[1,2], Ronald C. Inglehart[1], Christina Springstead Scanlon[1], Nickole Russo[1], Rajat Banerjee[1], Nisha J. D'Silva[1,3]

[1]Department of Periodontics and Oral Medicine, School of Dentistry, University of Michigan, Ann Arbor, MI, USA; [2]Department of Oral and Maxillofacial Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China; [3]Department of Pathology, University of Michigan Medical School, University of Michigan, Ann Arbor, MI, USA

BACKGROUND: In this study, we use a bioinformatics-based strategy to nominate a tumor suppressor gene cadherin-11 (CDH11) and investigate its role in growth and invasion in head and neck squamous cell carcinoma (HNSCC).
METHODS: Using the Oncomine™ database to compare HNSCC and normal specimens, CDH11 was nominated as having a role in HNSCC. CDH11 expression in HNSCC was evaluated by immunohistochemistry on a tissue microarray (TMA) and immunoblotting and immunofluorescence of cell lines. The functional impact of CDH11 on proliferation and invasion was evaluated after siRNA-mediated knockdown.
RESULTS: *In silico* analysis suggested that CDH11 is overexpressed in HNSCC compared to normal specimens. HNSCC TMA exhibited a small but significant increase in intensity and proportion of CDH11. By immunoblot analysis, CDH11 was higher in 4/7 HNSCC cell lines compared to normal keratinocytes; CDH11 was highly upregulated in UM-SCC-47 and UM-SCC-74A and detectable in UM-SCC-14A and UM-SCC-29 cell lines. Downregulation of CDH11 in both UM-SCC-29 and UM-SCC-47 using two different siRNAs enhanced proliferation and invasion.
CONCLUSION: CDH11 inhibits cell proliferation and invasion of HNSCC. This suggests that CDH11 functions as a tumor suppressor gene in head and neck cancer. Our findings emphasize the importance of verifying *in silico* findings with functional studies.

Correspondence: Nisha J. D'Silva, Department of Periodontics and Oral Medicine, School of Dentistry, University of Michigan, 1011 North University Ave, Room 5217, Ann Arbor, MI 48109-1078, USA. Tel: (734) 764 1543, Fax: (734) 764 2469, E-mail: njdsilva@umich.edu
Accepted for publication May 25, 2016

Introduction

In silico analysis of existing datasets has become an important approach in identifying tumor-specific networks and nominating molecular targets in head and neck squamous cell carcinoma (HNSCC) (1). Translational researchers use *in silico* analyses linked to clinical data to complement laboratory research. Meta-analyses of existing microarray data demonstrate correlations of markers across datasets within a cancer type and across clinical stages. As the importance of *in silico* analyses increases in translational research studies, multiple platforms have been assembled for bioinformatics analysis. The present study used Oncomine™, which is a platform for meta-analysis of microarray datasets each of which includes multiple normal and tumor samples (2). Using this approach, we identified that Cadherin11 (CDH11), also known as osteoblasts-cadherin, is differentially regulated in HNSCC and normal tissue.

CDH11, one of the type II classical cadherins, was first identified in osteoblasts where it is an integral membrane protein involved in cell–cell adhesion, potentially playing a role in development and maintenance of bone (3). CDH11 promotes invasion and metastasis in prostate and breast cancers, consistent with an oncogenic role (4, 5). In breast cancer, CDH11 promotes metastases to the bone, due to the high binding affinity of cancer cells for the strongly CDH11-expressing osteoblasts. (4). In contrast, in esophageal, colorectal and gastric cancers, CDH11 is silenced by methylation and has a tumor suppressor role (6, 7). In esophageal and nasopharyngeal cancer cells, CDH11 inhibits invasion and migration (7). Due to the variability in CDH11 function, it is important to consider the cellular context. In the present study, using an *in silico* approach, we nominated CDH11 as having a role in HNSCC and investigated the expression and function of CDH11 in HNSCC.

Materials and methods

In silico studies
The Oncomine™ database (Compendia Bioscience, Ann Arbor, MI, USA) was used for *in silico* studies. Eighteen

90

head and neck cancer datasets were identified using the search parameters 'Cancer Type: Head and Neck Cancer' and 'Analysis Type: Cancer vs. Normal Analysis'. Datasets from studies of adenoid cystic carcinoma, thyroid carcinomas and nasopharyngeal carcinomas were excluded. The following studies were retained: Cromer Head- Neck (8), Estilo Head-Neck (9), Ginos Head-Neck (10), Kuriakose Head-Neck (11), Peng Head-Neck and Peng Head-Neck 2 (12), Pyeon Multi-cancer (Tongue, Oropharyngeal, Floor of Mouth and Oral Cavity) (13), Schlingemann Head-Neck (14), Talbot Lung (included tongue) (15), Toruner Head-Neck (16), The Cancer Genome Atlas (TCGA) Head-Neck, Ye Head-Neck (17). A summary of CDH11 overexpression in multiple cancer types was generated. In addition, correlation between CDH11 and epithelial to mesenchymal transition (EMT) markers, E-Cadherin and Twist-1, was evaluated from datasets in Oncomine™.

GraphPad Prism® was used for statistical analyses. HNSCC datasets with mRNA expression data ($n = 15$) were identified in Oncomine™. Meta-analyses were performed as described (18). Expression of CDH11 was compared between normal and HNSCC samples by Student's t-test in each HNSCC dataset, and a P-value of <0.05 was determined to be statistically significant. Each statistically significant study was given an arbitrary value of '1' and non-significant studies were assigned a value of '0'. A one-sample t-test was performed for each set of values, and a one-sided P-value of <0.05 was considered statistically significant.

Immunohistochemistry
Immunostaining on formalin-fixed, paraffin-embedded tissue and scoring of staining intensity was performed as described (18) on a HNSCC tissue microarray (TMA) (US Biomax. Rockville, MD, USA). The CDH11 affinity purified rabbit polyclonal antibody (2.7 µg/ml) used for immunohistochemical studies was from R&D Systems. Rabbit IgG (Dako, Carpinteria, CA, USA) was used as a negative control at the same concentration as the primary antibody. For analysis of TMA data, interpretation and scoring were performed by a board-certified pathologist as described (18). The clinico-pathological parameters of the HNSCC cases and CDH11 intensity and proportion scores are included in Table S1.

Cell culture
UM-SCC cell lines were provided by Thomas Carey (University of Michigan). Cells were genotyped to confirm identity and cultured as described (18). All UM-SCC cell lines were maintained in Dulbecco's modified Eagle's medium (Gibco, Life Technologies, Grand Island, NY, USA) supplemented with 10% FBS and 1% penicillin/streptomycin. Immortalized keratinocytes, HOK16B, obtained from Dr. NH Park (UCLA), were cultured as described.

Transfection
To downregulate CDH11, HNSCC cells were transfected with siRNA (Dharmacon, Lafayette, CO). The sequences for each siRNA were: Non-Target 5′-GUGAUUUCAUAGC-GAGUUU-3′, siCDH11-7 5′-GGAAAUAGCGCCAAGUU

AG-3′ and siCDH11-8 5′-CCUUAUGACUCCAUUCAAA-3′. UM-SCC-47 and UM-SCC-29 were seeded in a 6-well plate and transfected with siRNA using RNAiMAX (Invitrogen, Carlsbad, CA, USA), according to the manufacturer's instructions.

Immunoblot
Lysates for detecting CDH11 were prepared using Red Loading Buffer Pack (Cell Signaling, Danvers, MA, USA). Lysates for detecting the other proteins were prepared using 1% NP40 lysis buffer (18). Antibodies used were CDH11 (A16652; Cell Signaling Technologies, Danvers, MA, USA), Twist-1 (25465-1-AP; Proteintech, Chicago, IL, USA), E-Cadherin (610182; BD Biosciences, Franklin Lakes, NJ, USA), GAPDH (AB2302; Millipore, Billerica, MA, USA), and Actin (612656; BD Biosciences).

Immunofluorescence staining
Cells were stained with E-cadherin (610182; BD Biosciences) in 0.3% triton X-100 overnight at 4°C. Cells were washed and incubated with secondary antibody and imaged on a Nikon Eclipse Ti microscope.

In vitro proliferation and invasion assay
At 24–48 h post-transfection, cells were seeded at equal densities (1×10^4 for UM-SCC-29, 2×10^4 for UM-SCC-47). Viable, non-viable, and total cells were quantified at 1, 3, and 5 days using the Countess assay system (Invitrogen) with trypan blue.

Cell invasion was assessed 24–72 h after transfection using the modified Boyden chamber assay with Transwell inserts coated with Matrigel (BD Biosciences), as described (18). Inserts, not coated with matrigel, were used as a control for migration.

Statistical analysis
P-values were calculated using the student's t-test, a P-value of less than 0.05 was accepted as significant. Correlation coefficients (Spearman correlation) denoted by r, together with a P-value, were computed to measure correlation between different genes.

Results
HNSCC datasets provide extensive data for in silico studies
The Oncomine™ database contained 986 datasets and 89 461 samples (accessed 04/24/2015). Of the available datasets, 36 were identified as 'Head and Neck Cancer' datasets. Figure 1 gives an overview of the content of these datasets. DNA or mRNA expression data are available for the datasets (Fig. 1A). While most datasets contain less than 75 samples, about 20% contain more than 151 samples (Fig. 1B). The data provided come from a range of sources, including cell panels, tissue panels and TCGA, which was compiled by the National Cancer Institute and National Human Genome Research Institute (Fig. 1C). The specimens used to generate the datasets include surgical specimens and samples collected by laser-capture microdissection, manual microdissection, and macrodissection (Fig. 1D). Several available search platforms for head and neck cancer dataset analysis are listed in Table 1.

Figure 1 Details of Head-Neck Cancer datasets. (A) A larger number of datasets provide mRNA expression (87%) levels than DNA copy-number analyses (13%). (B) While most of the sample sets have <75 samples (59%), 20% contain more than 151 samples. (C) Data are supplied by a range of sources including cell and tissue and data from sources including The Cancer Genome Atlas (TCGA), which is compiled by the National Cancer Institute and National Human Genome Research Institute. (D) Samples represent a variety of sources, including cell lines, surgical specimens, and both macro and micro dissections.

Table 1 Sample databases available for *in silico* studies in tumor/normal specimens

Database	Access information	Description
Cancer Gene Expression Database	http://lifesciencedb.jp/cged/ Freely searchable.	A database of gene expression from studies performed in Japanese institutions.
GENT – Gene Expression Across Normal and Tumor tissue	http://medical-genome.kribb.re.kr/GENT/ Freely searchable.	A database of comparative gene expression across normal and cancer tissues.
KEGG Database (Kyoto Encyclopedia of Genes and Genomes)	http://www.genome.jp/kegg/kegg1.html Freely searchable.	An integrated database of genomic and functional data, links genes to higher level functions.
Oncomine	https://www.oncomine.org/ Registration available to users from educational, government and non-profit institutions.	A compilation of cancer microarray data, search focus can be narrowed very finely.
RefSeq – The Reference Sequence Collection	http://www.ncbi.nlm.nih.gov/RefSeq/ Freely searchable, some content that it links to requires additional access privileges.	The American NIH database of DNA, RNA and protein sequences, provides detailed information on many of these genes and proteins.
The Tumor Gene Family of Databases	http://www.tumor-gene.org/Oral/oral.html Freely searchable.	A set of databases of tumor suppressors, potential oncogenes and cancer-inducing mutations.

Expression levels of biomarkers analyzed in the datasets can be linked to clinically relevant parameters including sample site, clinical outcomes, molecular subtypes, pathological subtypes, drug sensitivities, and patient demographics.

CDH11 is overexpressed in cancer tissue compared to normal tissue of patients in HNSCC
A summary of representative histograms detailing expression levels in individual studies used to compile the meta-analyses of CDH11 is shown in Fig. 2A. Table 2 illustrates systematic overexpression of CDH11 in HNSCC, including a meta-analysis of the expression level in cancer vs. normal across multiple datasets.

CDH11 is expressed in HNSCC tissue
In silico data suggested that CDH11 is overexpressed in HNSCC. In order to validate the *in silico* findings, the expression of CDH11 was investigated in tissues. In initial studies, the antibody was optimized for immunohistochemistry on paraffin-embedded colon cancer tissue and associated tumor stroma, which are known to express CDH11 (19). After finding that CDH11 appropriately stained these positive control tissues, a TMA containing human HNSCC tissues and normal oral tissues was immunostained. CDH11 had low expression in normal tissue, and exhibited low, medium or high staining in HNSCC (Fig. 2B). HNSCC samples on the TMA exhibited a small but significant increase in intensity of staining, and proportion of positive HNSCC cells when compared to normal tissues (Fig. 2C). These data confirm that CDH11 is expressed in HNSCC tissues at higher levels than normal tissue.

Multiple HNSCC cell lines as well as a non-malignant immortalized keratinocyte (HOK16B) cell line were immunoblotted with the CDH11 antibody (Fig. 3A). These data showed that CDH11 was upregulated in 4/7 HNSCC cell lines compared to HOK16B. Invasion is a significant

Figure 2 CDH11 is expressed in cancer. (A) Meta-analysis showing CDH11 upregulation in cancer compared to normal tissue. Individual study sets and accession numbers are identified in Table 2. (B) A TMA with HNSCC and normal tissues was incubated with CDH11 antibody followed by DAB detection. (bar = 100 μm) (C) The intensity and proportion were scored ($*P < 0.05$).

phenotype in HNSCC and is correlated with EMT and loss of cell–cell adhesion. Since CDH11 differentially modulates invasion, migration and metastasis in multiple cancers (4–7, 20), we investigated the correlation between expression of EMT markers and CDH11. Epithelial marker E-cadherin and mesenchymal marker Twist-1, and actin as a loading control, were immunoblotted (Fig. 3B) in HNSCC lysates. The data show that the E-Cadherin is upregulated in UM-SCC-(11A, 14A, 17B, 29, 47) cell lines and Twist-1 was downregulated in UM-SCC-(1, 11A, 14A, 17B, 29) cell lines compared to HOK16B; 4/5 of these cell lines [UM-SCC-(11A, 14A, 17B, 29)] showed an inverse relationship between Twist-1 and E-cadherin. To investigate the functional role of CDH11, we analyzed HNSCC datasets in Oncomine™ for potential correlation between CDH11 and EMT markers, E-cadherin and Twist-1. We found a dramatic positive correlation between CDH11 and E-cadherin (Fig. 3C) and a significant negative correlation between CDH11 and Twist-1 (Fig. 3D). The data suggested that the high level of CDH11 may promote E-cadherin and repress Twist-1 expression.

To confirm the bioinformatics data, UM-SCC-29 and UM-SCC-47, which express low and high CDH11 (Fig. 3A), were selected for functional studies. Two

individual siRNAs were screened and downregulation was verified by immunoblot (Fig. 3E,F). After CDH11 was downregulated, epithelial and mesenchymal markers were examined to determine whether CDH11 negatively regulates EMT (Fig. 3G,H). In UM-SCC-29, which has low endogenous CDH11, Twist-1 is inversely correlated with CDH11 expression, but the direct correlation with E-cadherin and CDH11 is less prominent (Fig. 3G). In UM-SCC-47, which has high endogenous CDH11, E-cadherin is directly correlated with CDH11 and inversely correlated with Twist-1 expression (Fig. 3H). Importantly, a spindle-like EMT morphologic appearance was observed after knockdown of CDH11 in HNSCC cells (Fig. 4A). Furthermore, the positive correlation between CDH11 and E-cadherin was confirmed by immunofluorescence (Fig. 4B). Thus, CDH11 expression is correlated with a reverse EMT phenotype, including upregulated epithelial marker E-cadherin and downregulated mesenchymal marker Twist-1.

CDH11 inhibits proliferation and invasion in vitro
In order to investigate the functional role of CDH11, proliferation and invasion assays were performed in UM-SCC-29 and UM-SCC-47 cell lines using two siRNAs, si7 and si8. Our data show that downregulation of CDH11 in

Table 2 Meta-analysis of CDH11 expression

Study	Accession number	Link to data	t-Test (d.f.)	P-value	Normal/cancer samples	Normal tissue type
1) Ginos Head-Neck	No accession number	http://www.ncbi.nlm.nih.gov/pubmed/14729608?dopt=Abstract	12.175 (52)	3.86e-17	13/41	Buccal Mucosa
2) Peng Head-Neck 2	GSE25103	http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE25103	4.921 (120)	1.46e-6	10/112	Oral Cavity
3) Estilo Head-Neck	GSE13601	http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE13601	4.101 (55)	6.91e-5	26/31	Tongue
4) Peng Head-Neck	GSE25099	http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE25099	3.809 (77)	1.93e-4	22/57	Oral Cavity
5) Talbot Lung	GSE3524	http://www.ncbi.nlm.nih.gov/pubmed/15833835?dopt=Abstract	3.67 (57)	3.17e-4	28/31	Lung and Tongue
6) Pyeon Tongue	GSE6791	http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE6791	3.726 (35)	6.13e-4	22/15	Oral Tissues
7) Pyeon Oropharyngeal	GSE6791	http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE6791	5.098 (26)	8.68e-4	22/6	Oral Tissues
8) Toruner Head-Neck	GSE3524	http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE3524	3.269 (18)	0.002	4/16	Squamous Cells
9) Cromer Head-Neck	GSE2379	http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE2379	4.773 (36)	0.004	4/34	Uvula
10) Pyeon Floor of Mouth	GSE6791	http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE6791	3.887 (25)	0.005	22/5	Oral Tissues
11) Pyeon Oral Cavity	GSE6791	http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE6791	3.371 (24)	0.018	22/4	Oral Tissues
12) Schlingemann Head-Neck	GSE1722	http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE1722	3.094 (2)	0.019	4/4	Hypopharynx and Oropharynx
13) Ye Head-Neck	GSE9844	http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE9844	1.117 (36)	0.137	12/26	Tongue
14) Kuriakose Head-Neck	GDS2520	http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE6631	0.884 (23)	0.223	22/3	Mucosa
15) TCGA Head-Neck (SCC)	GSE55543	http://tcgadata.nci.nih.gov/tcga/	−0.178 (817)	0.571	434/385	Blood and Head-Neck Parts
CDH11 Meta-Analysis (P = 0.05)	NA	http://gdac.broadinstitute.org/runs/stddata__2013_09_23/data/ NA	7.0156 (14)	0.0001	NA	NA
CDH11 Meta-Analysis (P = 0.001)	NA	NA	3.4925 (14)	0.0036	NA	NA

CDH11 expression is upregulated in HNSCC relative to normal tissue. Individual HNSCC studies examined the difference in CDH11 expression between normal and cancer tissues with two sample t-tests. The meta-analysis was then conducted as a one-sample t-test comparing the proportion of studies that were statistically significant at the 0.05 level with the proportion of studies expected to be significant at the 0.05 level. The 't-Test (d.f.)' column reports the statistical output of the original studies as presented on Oncomine. (d.f.: degrees of freedom).

Figure 3 CDH11 expression correlates with a reverse epithelial to mesenchymal transition (EMT) phenotype. (A) Whole cell lysates of Immortalized keratinocytes (HOK16B) as well as UM-SCC-1, -11A, -14A, -17B, -29, -47, -74A were immunoblotted with anti-CDH11; GAPDH was used as a loading control. (B) Whole cell lysates of Immortalized keratinocytes (HOK16B) as well as UM-SCC-1, -11A, -14A, -17B, -29, -47, -74A were blotted with E-Cadherin, Twist-1, and actin as a loading control. (C, D) Spearman analysis for correlation between CDH11 and EMT markers (E-Cadherin and Twist-1) were conducted from multiple HNSCC database (C: Rickman Head-Neck, Ginos Head-Neck, Slebos Head-Neck, Pyeon Multi-cancer, Toruner Head-Neck, Ye Head-Neck, O`Donnell Oral, Schlingemann Head-Neck, $n = 270$; D: Sengupta Head-Neck, Rickman Head-Neck, Pyeon Multi-cancer, Ye Head-Neck, Bittner Multi-cancer, $n = 191$) from Oncomine (oncomine.org). Numbers represent r values with significance ($P < 0.0001$, $P < 0.05$, respectively). Two individual siRNAs were investigated for efficiency in downregulating CDH11 in (E) UM-SCC-29 and (F) UM-SCC-47. After siRNA-mediated knockdown, cell lysates from UM-SCC-29 (G) and UM-SCC-47 (H) were immunoblotted with anti-E-Cadherin and anti-Twist-1. Actin was run as a loading control.

both cell lines by two different siRNAs significantly increased proliferation at 72 and 120 h (Fig. 4C). Invasion, an oncogenic phenotype that facilitates tumor spread, was also significantly enhanced by knockdown of CDH11 at 72 h (Fig. 4D). These findings are consistent with the reverse EMT phenotype observed in Fig. 3G,H. Together, the functional studies support a tumor suppressive role for CDH11 in HNSCC.

Discussion

Translational researchers are faced with the challenge of addressing the gap between experimental studies and implementation in clinical care. *In silico* investigations using multiple datasets provide researchers with a practical approach to enhancing benchtop investigations with clinically oriented data or to discovery of potential biomarkers. In the present study, we performed a meta-analysis of multiple datasets using the Oncomine™ platform. We observed that CDH11 is overexpressed in HNSCC relative to normal tissue across several datasets. Therefore, we investigated the expression and function of CDH11, and established that contrary to *in silico* findings, CDH11 has anti-proliferative and anti-invasive effects in HNSCC. In the context of a growing number of available genomic, transcriptomic, metabolomic and proteomic datasets, the present study highlights the importance of functionally validating *in silico* findings.

Cadherins are transmembrane glycoproteins that regulate homophilic intercellular adhesion by calcium-dependent

Figure 4 Downregulation of CDH11 in UM-SCC-29 and UM-SCC-47 cells promoted proliferation and invasion. (A) Morphology changes of UM-SCC-29 and UM-SCC-47 cells transfected with siNT or siCDH11 by phase-contrast microscopy. Original magnification, ×100 (bar = 200 μm). (B) UM-SCC29 and UM-SCC-47 cells were stained with Cadherin (green) antibodies and DAPI (blue) after transfection with siCDH11. (bar = 100 μm). (C) UM-SCC-29 and UM-SCC-47 cells were transfected with siCDH11 (si7, si8) or NT siRNA. UM-SCC-29 and UM-SCC-47 cells were seeded in triplicate at 48 h after transfection in a 24-well plate and cells were counted at 1, 3, and 5 days after seeding. Total viable cells are shown. *$P < 0.05$ at 72 h and at 120 h. (D) Cell invasion was assessed at 72 h in UM-SCC-29 and UM-SCC-47 cells transfected with siCDH11 (si7, si8) or NT siRNA. *$P < 0.05$ at 72 h.

interactions (21). Cadherins contain a negatively charged domain, which binds Ca^{2+} (3). The cytoplasmic domain is divergent among cadherin family members (3). There are over 80 members in the cadherin superfamily (3). CDH11 is a member of the 'classical' cadherin subclass of the cadherin superfamily (21). Type I Classical cadherins include E-cadherin/cadherin 1, N-cadherin/cadherin 2, R-cadherin/cadherin 4, P-cadherin or cadherin 3. Type II Classical cadherins include CDH11 (21). Other cadherins include protocadherins, desmosomal cadherins, seven-pass transmembrane cadherins, and Ret tyrosine kinase (21). Classical cadherins regulate cell–cell interactions, tissue homeostasis, and tissue morphogenesis; given these important roles, disruption of these proteins leads to disease (22). Cadherin homodimers on one cell bind homodimers on another cell to form transdimers that facilitate cell–cell adhesion (21).

The gene for CDH11 is located on chromosome 16 (3). CDH11 is usually expressed in mesenchymal cells and facilitates adhesion between these cells (23). CDH11 expression correlates with osteoblast-differentiation and promotes chondro-osteogenesis and inhibits adipogenesis (3, 21). Consistent with an oncogenic role, CDH11, promotes invasion of prostate cancer cells and metastasis to bone (5, 20). CDH11 expression is upregulated in colorectal tumors (24). In oral squamous cell carcinoma, a previous immunohistochemical study showed that CDH11 is overexpressed but did not perform functional studies (25). In the present study, *in silico* studies and TMAs of human HNSCC suggested that CDH11 is overexpressed in

HNSCC. Some HNSCC sections showed high CDH11 whereas in other sections, the expression was not as impressive. Together, these findings yielded an overall significant difference in expression of CDH11 between HNSCC and normal tissue. This is supported by immuno-blot analysis showing overexpression of CDH11 in four out of seven HNSCC cell lines compared to normal keratinocytes. This suggests that overexpression of CDH11 is cancer-specific and is overexpressed in some and not in other HNSCCs. This is consistent with the heterogeneity of HNSCC and emphasizes the importance of personalized medicine in HNSCC. Importantly, in functional studies, we found that downregulation of CDH11 promotes proliferation and enhances invasion, consistent with a tumor suppressor role for CDH11. These findings are consistent with the recently reported loss of CDH11 expression in melanoma as a widespread event (26). Similarly, CDH11 undergoes genomic deletion in retinoblastomas (6) and its loss correlates with increased invasion. Studies in retinoblastoma (6) and malignant pheochromocytoma (27) showed that CDH11 potently suppresses tumor metastasis. Moreover, CDH11 expression reduced metastatic potential in lung cancer and represented a beneficial prognostic factor in osteosarcoma (28). Since the oncogenic vs. tumor suppressive function of CDH11 varies by cancer, it is important to consider the specific cancer type. Furthermore, different tumors within a subtype may differ in CDH11 expression. In the emerging area of personalized medicine, variation in CDH11 expression may be relevant to tumor behavior.

Data mining of publically available datasets was used to nominate novel oncogenes having a role in epithelial-mesenchymal transition in HNSCC. This study was the first to analyze the expression of CDH11 using an *in silico* experiment and verify its tumor suppressor role in HNSCC. In this role, CDH11 inhibits invasion and proliferation in HNSCC. Interestingly, CDH11 expression is inversely correlated with EMT, which has been shown to be an important event in invasion (29). This may occur via the Wnt/β-catenin pathway. A previous study showed that CDH11 is a functional tumor suppressor and an important regulator of Wnt/β-catenin signaling involved in EMT, with frequent epigenetic inactivation in common carcinomas (7).We showed previously that β-catenin promotes invasion in HNSCC (30). Future studies are needed to investigate this possibility.

In summary, we analyzed CDH11 expression in HNSCC by meta-analysis of fifteen datasets in the Oncomine™ database. These findings were verified by expression studies in multiple cell lines and HNSCC tissue. Importantly, we observed that CDH11 is a tumor suppressor in functional studies. Further investigations are needed to determine the mechanism of CDH11-mediated inhibition of invasion.

Supporting Information

Additional Supporting Information may be found in the online version of this article:

Table S1 The clinico-pathological parameters of the HNSCC cases and CDH11 intensity and proportion scores.

References

1. Cirillo N. Merging experimental data and in silico analysis: a systems-level approach to autoimmune disease and cancer. *Expert Rev Clin Immunol* 2012; **8**: 361–72.
2. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, et al. Mining for regulatory programs in the cancer transcriptome. *Nat Genet* 2005; **37**: 579–83.
3. Yagi T, Takeichi M. Cadherin superfamily genes: functions, genomic organization, and neurologic diversity. *Genes Dev* 2000; **14**: 1169–80.
4. Pishvaian MJ, Feltes CM, Thompson P, et al. Cadherin-11 is expressed in invasive breast cancer cell lines. *Cancer Res* 1999; **59**: 947–52.
5. Huang CF, Lira C, Chu K, et al. Cadherin-11 increases migration and invasion of prostate cancer cells and enhances their interaction with osteoblasts. *Cancer Res* 2010; **70**: 4580–9.
6. Marchong MN, Yurkowski C, Ma C, et al. Cdh11 acts as a tumor suppressor in a murine retinoblastoma model by facilitating tumor cell death. *PLoS Genet* 2010; **6**: e1000923.
7. Li L, Ying J, Li H, et al. The human cadherin 11 is a pro-apoptotic tumor suppressor modulating cell stemness through Wnt/beta-catenin signaling and silenced in common carcinomas. *Oncogene* 2012; **31**: 3901–12.
8. Cromer A, Carles A, Millon R, et al. Identification of genes associated with tumorigenesis and metastatic potential of hypopharyngeal cancer by microarray analysis. *Oncogene* 2004; **23**: 2484–98.
9. Estilo CL, Oc P, Talbot S, et al. Oral tongue cancer gene expression profiling: identification of novel potential prognosticators by oligonucleotide microarray analysis. *BMC Cancer* 2009; **9**: 11.
10. Ginos MA, Page GP, Michalowicz BS, et al. Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck. *Cancer Res* 2004; **64**: 55–63.
11. Kuriakose MA, Chen WT, He ZM, et al. Selection and validation of differentially expressed genes in head and neck cancer. *Cell Mol Life Sci* 2004; **61**: 1372–83.
12. Peng CH, Liao CT, Peng SC, et al. A novel molecular signature identified by systems genetics approach predicts prognosis in oral squamous cell carcinoma. *PLoS One* 2011; **6**: e23452.
13. Pyeon D, Newton MA, Lambert PF, et al. Fundamental differences in cell cycle deregulation in human papillomavirus-positive and human papillomavirus-negative head/neck and cervical cancers. *Cancer Res* 2007; **67**: 4605–19.
14. Schlingemann J, Habtemichael N, Ittrich C, et al. Patient-based cross-platform comparison of oligonucleotide microarray expression profiles. *Lab Invest* 2005; **85**: 1024–39.
15. Talbot SG, Estilo C, Maghami E, et al. Gene expression profiling allows distinction between primary and metastatic squamous cell carcinomas in the lung. *Cancer Res* 2005; **65**: 3063–71.
16. Toruner GA, Ulger C, Alkan M, et al. Association between gene expression profile and tumor invasion in oral squamous cell carcinoma. *Cancer Genet Cytogenet* 2004; **154**: 27–35.
17. Ye H, Yu T, Temam S, et al. Transcriptomic dissection of tongue squamous cell carcinoma. *BMC Genom* 2008; **9**: 69.
18. Banerjee R, Russo N, Liu M, et al. TRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancer. *Nat Commun* 2014; **5**: 4527.
19. Torres S, Bartolome RA, Mendes M, et al. Proteome profiling of cancer-associated fibroblasts identifies novel proinflammatory signatures and prognostic markers for colorectal cancer. *Clin Cancer Res* 2013; **19**: 6006–19.
20. Chu K, Cheng CJ, Ye X, et al. Cadherin-11 promotes the metastasis of prostate cancer cells to bone. *Mol Cancer Res* 2008; **6**: 1259–67.
21. Marie PJ, Hay E, Modrowski D, et al. Cadherin-mediated cell-cell adhesion and signaling in the skeleton. *Calcif Tissue Int* 2014; **94**: 46–54.
22. Yap AS, Gomez GA, Parton RG. Adherens junctions revisualized: organizing cadherins as nanoassemblies. *Dev Cell* 2015; **35**: 12–20.
23. Alimperti S, Andreadis ST. CDH2 and CDH11 act as regulators of stem cell fate decisions. *Stem Cell Res* 2015; **14**: 270–82.
24. Bujko M, Kober P, Mikula M, et al. Expression changes of cell-cell adhesion-related genes in colorectal tumors. *Oncol Lett* 2015; **9**: 2463–70.
25. Choi P, Jordan CD, Mendez E, et al. Examination of oral cancer biomarkers by tissue microarray analysis. *Arch Otolaryngol Head Neck Surg* 2008; **134**: 539–46.
26. Mueller DW, Bosserhoff AK. MicroRNA miR-196a controls melanoma-associated genes by regulating HOX-C8 expression. *Int J Cancer* 2011; **129**: 1064–74.
27. Sandgren J, Andersson R, Rada-Iglesias A, et al. Integrative epigenomic and genomic analysis of malignant pheochromocytoma. *Exp Mol Med* 2010; **42**: 484–502.

28. Nakajima G, Patino-Garcia A, Bruheim S, et al. CDH11 expression is associated with survival in patients with osteosarcoma. *Cancer Genomics Proteomics* 2008; **5**: 37–42.

29. de Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. *Nat Rev Cancer* 2013; **13**: 97–110.

30. Goto M, Mitra RS, Liu M, et al. Rap1 stabilizes beta-catenin and enhances beta-catenin-dependent transcription and invasion in squamous cell carcinoma of the head and neck. *Clin Cancer Res* 2010; **16**: 65–76.

Acknowledgements

Conflict of interest statement

The authors declare that there are no conflict of interests.